<DOC>
	<DOCNO>NCT00002539</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Colony-stimulating factor G-CSF may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . It yet know whether chemotherapy surgery plus G-CSF effective chemotherapy surgery alone treat patient osteosarcoma . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy surgery without G-CSF treat patient newly diagnose osteosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Surgery With Without G-CSF Treating Patients With Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine overall disease-free survival patient newly diagnose osteosarcoma extremity treat conventional vs intensive cisplatin doxorubicin without filgrastim ( G-CSF ) definitive surgery . - Compare toxicity regimens patient . - Compare response patient treat regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive conventional doxorubicin ( DOX ) IV 4 hour day 1-3 cisplatin ( CDDP ) IV continuously day 1 . Treatment continue every 3 week 2 course . At week 6 , patient undergo amputation local resection base pretherapy image response chemotherapy . Beginning 2 week surgery , patient receive 4 additional course conventional chemotherapy . - Arm II : Patients receive intensive DOX CDDP day 1 plus filgrastim ( G-CSF ) subcutaneously day 4-13 . Treatment continue every 2 week 3 course . At week 6 , patient undergo definitive surgery arm I . Beginning 2 week surgery , patient receive 3 additional course intensive DOX CDDP G-CSF . Patients experience disease progression preoperative chemotherapy undergo surgery earlier schedule complete schedule chemotherapy ( 6 course ) surgery , discretion surgeon oncologist . Within 4 week limb-sparing procedure , patient inadequate margin undergo amputation , follow 2 week later chemotherapy . Patients follow monthly 6 month , every 2 month 6 month , every 3 month 1 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 500 patient accrue study .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven resectable osteosarcoma long bone extremity No parosteal ( juxtacortical ) , periosteal , Pagetoid , postirradiation sarcoma No distant metastases PATIENT CHARACTERISTICS : Age : 40 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm^3 OR WBC least 3,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.2 mg/dL Renal : Glomerular filtration rate least 60 mL/min Cardiovascular : No history cardiac dysfunction Other : No prior concurrent malignancy except basal cell skin cancer OR Carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>localize osteosarcoma</keyword>
</DOC>